Thursday, 20 April 2017

Analabs - hidden gems??


http://www.analabs.com.my/images/logo.gif

I have this 'low profile and probably not known to many' stock in my portfolio, I wish to do some write up on this company if this is also your cup of tea.

Analabs - Background

Analabs has been involved in the environmental and industrial related business since 1936 in Singapore and 1965 in Malaysia. With more than 40 years of experience in this industry, it has been able to chart its success in the environmental business and has positioned itself as one of the pioneers in providing quality laboratory testing by meeting ISO/IEC Guide 17025 and ISO 9002 standards.

Listed on the Second Board of Bursa in year 2000 with initial paid up capital of Rm40 mil (40 mil shares @Rm1.00 each), IPO price was at Rm1.70 per share. There was a 1 for 2 bonus issue in 2002 and its enlarged share capital is 60 mil shares now.

It principal business consists of the followings:-

  1. Manufacturing, formulation and sale of resin, chemicals & building materials
  2. Recovery and sale of recycled products
  3. Contract work, Pipe laying & rehabilitation

 Past 5 years Financial Performance

Income Statement

2017 (Q3)
2016
2015
2014
2013
2012
RM'000
RM'000
RM'000
RM'000
RM'000
RM'000
Revenue
         117,055
       155,176
        142,088
        140,324
        147,376
        120,465
Cost of sales and services
          (75,480)
     (122,509)
       (113,830)
       (116,949)
       (119,508)
         (88,929)
Gross profit
           41,575
         32,667
           28,258
           23,375
           27,868
           31,536
Other operating income
              2,294
            6,975
             3,776
             7,486
             4,062
             3,176
Operating expenses
          (31,853)
        (23,744)
         (22,838)
         (18,070)
         (17,764)
         (16,660)
Profit from operation, EBIT
           12,016
         15,898
             9,196
           12,791
           14,166
           18,052
Finance costs
               (747)
             (617)
               (986)
               (926)
               (540)
               (206)
EBT
           11,269
         15,281
             8,210
           11,865
           13,626
           17,846
Taxation
            (2,188)
          (2,926)
           (1,866)
           (2,770)
           (4,080)
           (3,269)
Net Income
              9,081
         12,355
             6,344
             9,095
             9,546
           14,577
DPS, sen
3.25
              3.00
               3.00
               4.13
               5.50
5.00
EPS
0.16
0.24
0.11
0.16
0.16
0.24

 

Operating Expenses - FY17 (3 Qtrs) > FY16 Full year, I believe was due to classification issue between COS & Operating Exp as FY16 Annual Report full year Operating Expenses was lower than Q3 FY16. That also explained why Gross Profit for FY17 (3 Qtrs) > FY16 full year.

Cashflow

2017 (Q3)
2016
2015
2014
2013
2012
RM'000
RM'000
RM'000
RM'000
RM'000
RM'000
Net Cash generated from operations
            10,563
           29,046
            18,470
        19,530
         17,506
            8,587
Free Cash Flow
              9,485
           29,055
            16,599
        11,429
         16,902
            2,080

Financial Position

2017 (Q3)
2016
2015
2014
2013
2012
Assets
RM'000
RM'000
RM'000
RM'000
RM'000
RM'000
Current asset
Cash and cash equivalent
               45,281
             39,055
        33,195
        25,203
        29,075
         20,466
Other Assets
               51,812
             59,076
        63,891
        71,195
        64,054
         49,314
Total current assets
               97,093
             98,131
        97,086
        96,398
        93,129
         69,780
Non-current assets
Property, plant and equipment
            147,515
          150,115
      155,127
      159,840
        95,228
91273
Intangible assets/ DTA
                 9,804
               9,915
           9,804
           9,755
           8,397
           7,089
Investments
               29,841
             31,426
        22,722
        14,833
           7,514
         15,365
Total non-current assets
            187,160
          191,456
      187,653
      184,428
      111,139
      113,727
Total Assets, TA
            284,253
          289,587
      284,739
      280,826
      204,268
      183,507
Short-term loan & borrowings
               11,292
             11,961
        19,707
        10,488
        10,874
3163
Other Payables
               18,957
             28,779
        22,167
        24,861
        19,731
         11,967
Total current liabilities, CL
               30,249
             40,740
        41,874
        35,349
        30,605
         15,130
Long-term loan
                 6,009
               9,457
        13,591
17859
Deferred tax & Others
               18,570
             18,138
        19,360
20596
10406
9590
Total non-current liabilities
               24,579
             27,595
        32,951
        38,455
        10,406
           9,590
Total liabilities
               54,828
             68,335
        74,825
        73,804
        41,011
         24,720
Equity
Common stock
               66,272
             60,024
        60,024
        60,024
        60,024
         60,024
Reserve
               43,945
             50,213
        49,467
        51,189
        14,234
         16,934
Retained earnings
            121,094
          113,097
      101,528
        96,343
        88,999
81829
Total common equity, E
            231,311
          223,334
      211,019
      207,556
      163,257
      158,787
Minority interest
               (1,886)
             (2,082)
         (1,105)
            (534)
 
 
Total Equity
            229,425
          221,252
      209,914
      207,022
      163,257
      158,787
Total liabilities and equity
            284,253
          289,587
      284,739
      280,826
      204,268
      183,507
No of shares outstanding ('000)
               56,105
             56,259
        60,024
        60,024
        60,024
         60,024
NA value/share
                   4.1
                 3.9
             3.5
             3.5
             2.7
             2.6

 

Key Financial Metrics


Key Metrics
 
 
Price
2.25
Intrinsic Value
3.7
MOS (DCF)
39%
Dividend yield
1.4%
P/FCF
                         8.9
PB
                      0.55
PE
                      10.5
EV/EBIT
                         4.2
FCF/ Market cap  ( cash yield)
11%
ROIC (Average)
6%
Average ROE
5%
EY = EBIT/EV
24%
 
 

The negative from the metrics – ROIC and ROE

  1. Low ROIC – high PPE value mainly in land & building pull down the ROI, fortunately it does not require replacement such as Plant & equipment, hence, its' FCF is still very strong.
  2. Low ROE – mainly due to low dividend payout(ranging from 10% to 30%) and company retained most of the profit and resulting in high Equity value but unable to generate more return from the reserve retained.
    Both these are signs that management are not efficient in resource utilisation and not able to invest for higher return.

The Positive from the metrics – FCF, EV/EBIT, PB

  1. Strong FCF as low requirement in capital assets replacement ( cash yield at average 11%)
  2. Low EV/EBIT 4.2 appears cheap from valuation point of view (Earning yield at 24%)
  3. Low Price to Book - 0.55  (45% discount to book value – cash, Maybank share + land & building selling to us at 45% discount)
  4. PE of 10.5 seems ok.

Indicative Valuation

Current Market Capitalisation : 56mil (net of treasury shares) @Rm2.25 = Rm 126 mil

 DCF method : Rm3.70

 – derived from Discounted Cashflow (DCF) basing on average FCF from the last 6 years, discount rate at 11% and growth at 2% p.a. This provide a margin of safety of 39%.

 

This is further supported by its Net Asset value of Rm4.1 per share. At Rm2,25 now, it is actually 45% discount to net asset value.

Assets mainly consists of: 

Cash                                               Rm 45.3 mil ( 80 sen per share, net of debt will be 50 sen per share)

Investment                                    Rm 29.8 mil (mainly investment in Maybank shares as announced in Apr 17, worth 53 sen per share)

PPE                                                  Rm 147.5 mil (mainly land & building, which has been revalued in 2014)

  

Past 6 years share price performance

ANALABS RESOURCES BHD (7083) Chart

 Shareholding as of 29 Jul 2016

1 KAN YOW KHEONG                                                                                      38.01%

2 KAN YOW KHEONG                                                                                      18.16%

 Mr YK Kan is holding 56% of Analabs and top 30 shareholders hold 85% of the shares, hence, the liquidity of the shares is quite low.

 

Any near term catalyst??

 Business prospect – the business has been relatively stable and Analabs has attempted to expand the business but did not bring much results. In its 2016 Annual Report, it has highlighted that it has downsized the Singapore operation that is not performing to cut operating cost and will not expand or venture into new business in the near term. It appears that this is a boring company with not much excitement in financial performance or corporate news. Hence, it does not get much attention from investors as it is really a dull and boring counter.
I tried to imagine if I were Mr Kan, what would I do? Well, I would privatise it (only need Rm55 mil for the balance 44%) and I can easily get back my money from the cash + investment in Maybank shares. ( must learn from Maxis, Astro and so many others, privatise first and put up a much higher value for re-listing). Obviously Mr Kan is also not keen on corporate exercise, even though with high net asset per share and low liquidity, it has only done a bonus issue back in 2002 (15 years back, It was due to the requirement for main board transfer - min Rm60 mil share cap then). He probably knows that does not create value.  

 As for me, if it is purely an asset based value stock (Net Asset/share = Rm4.1), may not excite me too. However, when it is also supported by strong free cashflow of average Rm15 million per year (market cap at Rm126 mil, cash yield >10%), I am willing to ride with Junior Kan (recently re-designated to Executive position)  if he will bring excitement to Analabs and how the cash reserve can be utilised for higher return or higher dividend to be considered. Yes, hope is not strategy, in this case, it only has opportunity cost but limited risk and based on DCF valuation, there is 39% margin of safety (60% upside potential). Yes, I will camp here for a while.

7 comments:

  1. Hi, great analysis. I'm not an expert, but wish to share some ideas.

    Stock price will normally move up if profit up or future profit up.

    Wish you can identify these kind of stocks, eg increase in demands, expansion of production lines, entering new markets, completion of new plants, new products, etc.

    Hope u can spend more time to indentify and analyse these kind of stocks, rather than spend time analysing stocks that lack "clear" prospect (as mentioned in article above).
    Just my personal opinion, hope u dont mind.

    ReplyDelete
    Replies
    1. Agree with your thought and appreciate your comment too. Yes, will continue to search for undervalue stocks with clear catalyst. Analabs is a undervalue stock but the lack of clear catalyst make it not so sexy.




      Delete
  2. As expected, there was reclassification in Cost of sales and Other Operating Expenses in Q4, which appears to me a obvious mistake. In addition, lower profit after tax for Q4 YOY was due to tax provision. What puzzled me is that company did not explain any of the above in notes at all. Do note that fair value gain on securities that go into other comprehensive income has improved the NTA further to Rm4.22. Can company declare more dividend to entice investors so as increase its valuation? Management should leverage on strong cash position and healthy cash flow to enhance value. Will see whether major shareholder is willing to share with minority.

    ReplyDelete
  3. Junior Kan accumulated another 1 mil shares in Analabs. Any privatisation plan in mind?

    ReplyDelete
  4. An insider buying has pushed up the price over the last 2 weeks, something exciting coming?

    ReplyDelete
  5. Exceptional latest profit mainly from other income - gain on disposal of subsid and dividend.

    Not many shareholders can enjoy this profit as it will be retained as always, and share price wont appreciate much.
    Institutional investors would not come in as it is lack of liquidity, how would minority shareholders reap the benefits of higher profit/better performance - if not from dividend or share price gain? I supposed this is value trap and not many shareholders would want to wait till Mr Kan decides to unlock its value, if, only if that ever happen.

    ReplyDelete
  6. Though I do not own any share of Analabs now, but I do take a look at it from time to time. I noted in the more recent financial statements the company is using margin trading financing to acquire listed investment ( i believe its Maybank & RHB as per their announcement). I do not like when management try to borrow and invest in unrelated business, worst all dividend from these investments are not re-distribute to shareholders. Yes, they may privatise the company as more and more reserve kept within the company and not distributed to minority shareholders.

    ReplyDelete

Are there many low hanging fruits in stock market now?

When I was a little kid and lived in a small village, one of my activities to pass time was looking for low hanging fruits from mango, rose ...